id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S12873 R48624 |
Thomas (Topiramate) (Controls exposed to Lamotrigine, sick), 2021 | Cardiac malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.90 [0.07;50.68] C excluded (control group) |
0/9 1/50 | 1 | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12875 R48636 |
Thomas (Topiramate) (Controls unexposed, sick), 2021 | Cardiac malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 2.05 [0.11;38.10] C | 0/9 9/340 | 9 | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8575 R28526 |
Tomson (Topiramate), 2018 | Cardiac malformations | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 3.35 [0.96;11.71] C | 3/152 15/2,514 | 18 | 152 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10297 R37721 |
Vajda (Topiramate) (Controls exposed to Lamotrigine, sick), 2013 | Cardiac Malformations | at least 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.02 [0.05;20.14] C excluded (control group) |
0/44 3/315 | 3 | 44 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10298 R37731 |
Vajda (Topiramate) (Controls unexposed, sick), 2013 | Cardiac Malformations | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 1.11 [0.04;27.86] C | 0/44 1/147 | 1 | 44 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10221 R37445 |
Hernández-Díaz (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2012 | Cardiovascular anomalies | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.45 [0.15;14.00] C | 1/359 3/1,562 | 4 | 359 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8569 R28510 |
Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 | Cardiac | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 2.60 [0.14;49.43] C | 0/28 4/647 | 4 | 28 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 5 studies | 2.47 [0.98;6.24] | 36 | 592 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Topiramate) (Controls unexposed, sick; 2: Topiramate; 3: Topiramate) (Controls unexposed, sick; 4: Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications; 5: Topiramate) (Controls exposed to Lamotrigine, sick;
Asymetry test p-value = 0.1127 (by Egger's regression)
slope=1.6661 (0.3703); intercept=-0.7784 (0.3500); t=2.2237; p=0.1127
excluded 10297, 12873